Guerin PJ, Olliaro P, Sundar S, Boelaert M, Croft SL, Desjeux P, Wasunna MK, Bryceson AD (2002) Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis 2: 494–501. doi: 10.1016/S1473-3099(02)00347-X
[2]
Olliaro PL, Guerin PJ, Gerstl S, Haaskjold AA, Rottingen JA, Sundar S (2005) Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 5: 763–774. doi: 10.1016/S1473-3099(05)70296-6
[3]
Lira R, Sundar S, Makharia A, Kenney R, Gam A, Saraiva E, Sacks D (1999) Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani. J Infect Dis 180: 564–567. doi: 10.1086/314896
[4]
Croft SL, Sundar S, Fairlamb AH (2006) Drug resistance in Leishmaniasis. Clin Microbiol Rev 19: 111–126. doi: 10.1128/CMR.19.1.111-126.2006
[5]
Hasker E, Singh SP, Malaviya P, Singh RP, Shankar R, Boelaert M, Sundar S (2010) Management of visceral leishmaniasis in rural primary health care services in Bihar, India. Trop Med Int Health 15: 55–62. doi: 10.1111/j.1365-3156.2010.02562.x
[6]
Ravenscroft P, Brammer H, Richards K (2009) Arsenic pollution: a global synthesis. Chichester: John Wiley & Sons. 588 p.
[7]
Yan S, Jin L, Sun H (2005) 51Sb antimony in medicine. In: Gielen M, Tiekink ERT, editors. Metallotherapeutic drugs & metal-based diagnostic agents, The use of metals in medicine. pp. 441–461.
[8]
Dey S, Papadopoulou B, Haimer A, Roy G, Grondin K, Dou D, Rosen BP, Ouellette M (1994) High level arsenite resistance in Leishmania tarentolae is mediated by an active extrusion system. Mol Biochem Parasitol 67: 49–57. doi: 10.1016/0166-6851(94)90095-7
[9]
Mazumder DNG (2005) Effect of chronic intake of arsenic-contaminated water on liver. Toxicol Appl Pharmacol 206: 169–175. doi: 10.1016/j.taap.2004.08.025
Sundar S, Mondal D, Rijal S, Bhattacharya S, Ghalib H, Kroeger A, Boelaert M, Desjeux P, Richter-Airijoki H, Harms G (2008) Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal—the challenges for diagnosis and treatment. Trop Med Int Health 13: 2–5. doi: 10.1111/j.1365-3156.2007.01974.x
[12]
Singh RK, Pandey HP, Sundar S (2006) Visceral leishmaniasis (kala-azar): challenges ahead. Indian J Med Res 123: 331–344.
[13]
Mondal D, Singh SP, Kumar N, Joshi A, Sundar S, Das P, Siddhivinayak H, Kroeger A, Boelaert M (2009) Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis 3: e355. doi:10.1371/journal.pntd.0000355.
[14]
Peters W (1981) The treatment of Kala-Azar - new approaches to an old problem. Indian J Med Res 73: 1–18.
[15]
Thakur CP (1984) Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis). Trans R Soc Trop Med Hyg 78: 391–398. doi: 10.1016/0035-9203(84)90131-7
[16]
Thakur CP, Kumar M, Kumar P, Mishra BN, Pandey AK (1988) Rationalisation of regimens of treatment of kala-azar with sodium stibogluconate in India: a randomised study. Br Med J (Clin Res Ed) 296: 1557–1561. doi: 10.1136/bmj.296.6636.1557
[17]
Chakraborti D, Mukherjee SC, Pati S, Sengupta MK, Rahman MM, Chowdhury UK, Lodh D, Chanda CR, Chakraborty AK, Basul GK (2003) Arsenic groundwater contamination in Middle Ganga Plain, Bihar, India: a future danger? Environ Health Perspect 111: 1194–1201. doi: 10.1289/ehp.5966
[18]
Rijal S, Chappuis F, Singh R, Bovier PA, Acharya P, Karki BMS, Das ML, Desjeux P, Loutan L, Koirala S (2003) Treatment of visceral leishmaniasis in south-eastern Nepal: decreasing efficacy of sodium stibogluconate and need for a policy to limit further decline. Trans R Soc Trop Med Hyg 97: 350–354. doi: 10.1016/S0035-9203(03)90167-2
[19]
Mubayi A, Castillo-Chavez C, Chowell G, Kribs-Zaleta C, Siddiqui NA, Kumar N, Das P (2010) Transmission dynamics and underreporting of Kala-azar in the Indian state of Bihar. J Theor Biol 262: 177–185. doi: 10.1016/j.jtbi.2009.09.012
[20]
Payne D (1988) Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today 4: 112–115. doi: 10.1016/0169-4758(88)90042-7
[21]
Deshingkar P, Kumar S, Chobey HK, Kumar D (2006) The role of migration and remittances in promoting livelihoods in Bihar. London: Overseas Development Institute. 48 p.
[22]
Vanaerschot M, Maes I, Ouakad M, Adaui V, Maes L, De Doncker S, Rijal S, Chappuis F, Dujardin JC, Decuypere S (2010) Linking in vitro and in vivo survival of clinical Leishmania donovani strains. PLoS ONE 5: e12211. doi:10.1371/journal.pone.0012211.
[23]
El Fadili K, Messier N, Leprohon P, Roy G, Guimond C, Trudel N, Saravia NG, Pavadopoulou B, Legare D, Ouellette M (2005) Role of the ABC transporter MRPA (PGPA) in antimony resistance in Leishmania infantum axenic and intracellular amastigotes. Antimicrob Agents Chemother 49: 1988–1993. doi: 10.1128/AAC.49.5.1988-1993.2005
[24]
Haimeur A, Brochu C, Genest PA, Papadopoulou B, Ouellette M (2000) Amplification of the ABC transporter gene PGPA and increased trypanothione levels in potassium antimonyl tartrate (SbIII) resistant Leishmania tarentolae. Mol Biochem Parasitol 108: 131–135. doi: 10.1016/S0166-6851(00)00187-0
[25]
Bern C, Chowdhury R (2006) The epidemiology of visceral leishmaniasis in Bangladesh: prospects for improved control. Indian J Med Res 123: 275–288.
[26]
Argos M, Kalra T, Rathouz PJ, Chen Y, Pierce B, Parvez F, Islam T, Ahmed A, Rakibuz-Zaman M, Hasan R, Sarwar G, Slavkovich V, van Geen A, Graziano J, Ahsan H (2010) Arsenic exposure from drinking water, and all-cause and chronic-disease mortalities in Bangladesh (HEALS): a prospective cohort study. Lancet 376: 252–258. doi: 10.1016/S0140-6736(10)60481-3
[27]
Sohel N, Persson LA, Rahman M, Streatfield PK, Yunus M, Ekstrom EC, Vahter M (2009) Arsenic in drinking water and adult mortality a population-based cohort study in rural Bangladesh. Epidemiology 20: 824–830. doi: 10.1097/EDE.0b013e3181bb56ec
[28]
Vahter M (1999) Methylation of inorganic arsenic in different mammalian species and population groups. Sci Prog 82: 69–88.
[29]
Raab A, Feldmann J (2005) Arsenic speciation in hair extracts. Anal Bioanal Chem 381: 332–338. doi: 10.1007/s00216-004-2796-6
[30]
Das S, Santra A, Lahiri S, Mazumder DNG (2005) Implications of oxidative stress and hepatic cytokine (TNF-alpha and IL-6) response in the pathogenesis of hepatic collagenesis in chronic arsenic toxicity. Toxicol Appl Pharmacol 204: 18–26. doi: 10.1016/j.taap.2004.08.010
[31]
Mukhopadhyay R, Rosen BP, Pung LT, Silver S (2002) Microbial arsenic: from geocycles to genes and enzymes. FEMS Microbiol Rev 26: 311–325. doi: 10.1111/j.1574-6976.2002.tb00617.x
[32]
Berman JD, Gallalee JV, Hansen BD (1987) Leishmania mexicana uptake of sodium stibogluconate (pentostam) and pentamidine by parasite and macrophages. Exp Parasitol 64: 127–131. doi: 10.1016/0014-4894(87)90018-X
[33]
Bhattacharjee H, Carbrey J, Rosen BP, Mukhopadhyay R (2004) Drug uptake and pharmacological modulation of drug sensitivity in leukemia by AQP9. Biochem Biophys Res Commun 322: 836–841. doi: 10.1016/j.bbrc.2004.08.002
[34]
Dey S, Ouellette M, Lightbody J, Papadopoulou B, Rosen BP (1996) An ATP-dependent As(III)-glutathione transport system in membrane vesicles of Leishmania tarentolae. Proc Natl Acad Sci U S A 93: 2192–2197. doi: 10.1073/pnas.93.5.2192
[35]
Légaré D, Richard D, Mukhopadhyay R, Stierhof YD, Rosen BP, Haimeur A, Papadopoulou B, Ouellette M (2001) The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J Biol Chem 276: 26301–26307. doi: 10.1074/jbc.M102351200
[36]
Ashutosh , Sundar S, Goyal N (2007) Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol 56: 143–153. doi: 10.1099/jmm.0.46841-0
[37]
Mittal MK, Rai S, Ravinder A, Gupta S, Sundar S, Goyal N (2007) Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg 76: 681–688.
[38]
Wyllie S, Cunningham ML, Fairlamb AH (2004) Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovani. J Biol Chem 279: 39925–39932. doi: 10.1074/jbc.M405635200
[39]
Brochu C, Wang JY, Roy G, Messier N, Wang XY, Saravia NG, Ouellette M (2003) Antimony uptake systems in the protozoan parasite Leishmania and accumulation differences in antimony-resistant parasites. Antimicrob Agents Chemother 47: 3073–3079. doi: 10.1128/AAC.47.10.3073-3079.2003
[40]
Wyllie S, Vickers TJ, Fairlamb AH (2008) Roles of trypanothione S-transferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob Agents Chemother 52: 1359–1365. doi: 10.1128/AAC.01563-07
[41]
Wyllie S, Mandal G, Singh N, Sundar S, Fairlamb AH, Chatterjee M (2010) Elevated levels of tryparedoxin peroxidase in antimony unresponsive Leishmania donovani field isolates. Mol Biochem Parasitol 173: 162–164. doi: 10.1016/j.molbiopara.2010.05.015
[42]
Rijal S, Yardley V, Chappuis F, Decuypere S, Khanal B, Singh R, Boelaert M, De DS, Croft S, Dujardin JC (2007) Antimonial treatment of visceral leishmaniasis: are current in vitro susceptibility assays adequate for prognosis of in vivo therapy outcome? Microbes Infect 9: 529–535. doi: 10.1016/j.micinf.2007.01.009
[43]
Seifert K, Escobar P, Croft SL (2010) In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother 65: 508–511. doi: 10.1093/jac/dkp500
[44]
Thakur CP, Narayan S, Ranjan A (2004) Epidemiological, clinical & pharmacological study of antimony-resistant visceral leishmaniasis in Bihar, India. Indian Journal of Medical Research 120: 166–172.
[45]
Sundar S (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849–854. doi: 10.1046/j.1365-3156.2001.00778.x
[46]
Central Ground Water Board (2010) Groundwater quality in shallow aquifers of India. 117 p.
